Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
Koichi Furukawa, Tatsuya Nagano, Motoko Tachihara, Masatsugu Yamamoto, Yoshihiro Nishimura
Abstract
Although immunotherapy has led to durable responses in diverse cancers, unfortunately, there has been limited efficacy and clinical response rates due to primary or acquired resistance to immunotherapy. To maximize the potential of immunotherapy, combination therapy with antiangiogenic drugs seems to be promising. Some phase III trials showed superiority for survival with the combination of immunotherapy and antiangiogenic therapy. In this study, we describe a synergistic mechanism of immunotherapy and antiangiogenic therapy and summarize current clinical trials of these combinations.
Topics & Concepts
ImmunotherapyMedicineClinical trialCancerAntiangiogenic therapyCancer immunotherapyCancer therapyCombination therapyOncologyInternal medicineImmunotherapy and Immune ResponsesCAR-T cell therapy researchCancer Immunotherapy and Biomarkers